Adenosine is named as an intervention in 2 current clinical trials in our Sweden, Denmark and Norway registers. 2 are recruiting patients now. All registered phases are Phase 4. The sponsor with the most trials is Region Skane (1). The most-studied condition is Chronic Coronary Syndrome. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
NCT04666454 · ClinicalTrials.gov ↗ · Takotsubo Syndrome
|
Phase 4 | Recruiting | Vastra Gotaland Region | Sweden, Denmark, Norway |
|
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
NCT06578234 · ClinicalTrials.gov ↗ · Chronic Coronary Syndrome, Coronary Artery Disease, Ischemic Heart Disease
|
Phase 4 | Recruiting | Region Skane | Sweden |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Adenosine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study
2025-522060-32-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 2 | Ongoing | CorFlow Therapeutics AG, CorFlow Therapeutics AG | Netherlands, Spain, France |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Adenosine on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Region Skane | 1 |
| Vastra Gotaland Region | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Sweden | 2 | 2 |
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Norway | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Sweden, Denmark and Norway registers name Adenosine as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in Sweden, 1 with sites in Denmark and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Region Skane (1) and Vastra Gotaland Region (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Adenosine, for example Adenocor 3 mg/ml solution for injection (Sanofi-Aventis Ireland Limited T/A SANOFI). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 3 entries for Adenosine: 3 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Adenosine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Adenosine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Adenosine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.